DIVI'S LABORATORIES LTD.

Divis Laboratories Ltd has announced the closure of its trading window for dealing in the company's securities. The window will be shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ended September 30, 2026. This measure is in accordance with the company's Code of Conduct for Designated Persons and Insiders. The specific date for the Board meeting to approve these financial results will be communicated later.

Divis Laboratories Ltd announced the outcome of its Board meeting held on August 01, 2026. The Board approved the unaudited financial results for the quarter ended June 30, 2026, both on a standalone and consolidated basis. The company also approved the appointment of Mr. B. Vara Prasad and Mr. J. Srinivasa Rao as Senior Management Personnel, effective from August 01, 2026. The meeting commenced at 10:15 Hrs and concluded at 11:20 Hrs.

Divis Laboratories Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a total income of ₹3037 Crores and a profit after tax of ₹891 Crores. The Board of Directors also approved the appointment of two new Senior Management Personnel: Mr. B. Vara Prasad and Mr. J. Srinivasa Rao, effective August 01, 2026. The financial results include standalone and consolidated statements along with the statutory auditors' limited review report.

Divis Laboratories Ltd has announced the retirement of two key senior management personnel: Mr. L. Ramesh Babu, Vice President (Procurement), and Mr. D. Madhu Babu, Vice President (Projects). Both will cease to be Senior Management Personnel of the company effective from the close of business hours on July 31, 2026. This intimation is made as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Divis Laboratories Ltd has announced that its Board of Directors will convene on August 1, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Concurrently, the trading window for the company's securities, which was closed from July 1, 2026, will remain shut until 48 hours after the declaration of these financial results, extending its closure until August 3, 2026.

Divis Laboratories Ltd has announced its 36th Annual General Meeting (AGM) will be held on August 10, 2026, at 10:00 a.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company will consider ordinary business including the adoption of audited financial statements for FY26, declaration of a dividend of ₹30 per equity share, and the re-appointment of directors Mr. N.V. Ramana and Dr. Kiran S. Divi. Electronic voting facilities will be available to members from August 6 to August 9, 2026.

Divis Laboratories Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report, which forms part of the Annual Report, details the company's operations, employee data, and market presence. Key disclosures include that the company's business activities, primarily the manufacture of Active Pharmaceutical Ingredients, Intermediates, and Nutraceuticals, account for 100% of its turnover. Exports constitute 89% of the total turnover, serving customers in 80 countries. The report also provides data on employee demographics, including a focus on differently-abled individuals and gender representation, as well as employee turnover rates.

Divis Laboratories Ltd has announced its 36th Annual General Meeting (AGM) will be held on Monday, August 10, 2026, at 10:00 a.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The company is sending the Notice of the AGM and the Annual Report for the financial year 2025-26 electronically to members with registered email addresses. For members without registered emails, a web-link to the Annual Report on the company's website (https://www.divislabs.com/investor-relations/reports-and-filings/annual-reporting/) will be provided. The facility for remote e-voting will be available from August 6, 2026, 9:00 a.m. IST to August 9, 2026, 5:00 p.m. IST, with a cut-off date of August 3, 2026.

Divis Laboratories Ltd has announced the closure of its trading window for designated persons and their immediate relatives. The window will be shut from July 01, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The exact date of the board meeting to approve these results will be communicated later. This measure is in accordance with the company's internal code of conduct for insider trading.

Divi's Laboratories Limited's Board of Directors has recommended a dividend of ₹30 per fully paid-up Equity Share (1,500%) for the Financial Year ended March 31, 2026. This dividend, if approved by shareholders at the 36th AGM on August 10, 2026, will be distributed on or after August 14, 2026. The record date for eligibility is July 24, 2026. The company has also communicated details regarding Tax Deducted at Source (TDS) on dividends to shareholders, outlining rates and documentation requirements for exemption or lower deduction for both resident and non-resident shareholders.